By Denny Jacob
Anavex Life Sciences shares rose 9.4% to $6.86 following an initiated process for submitting an application to European regulators regarding the marketing of blarcamesine, an Alzheimer’s treatment.
The stock is down 26% on the year.
The…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here
